Innovation and Patents - In 2023, the company was awarded the 24th China Patent Excellence Award for its invention patent related to a biological preparation method for preventing and controlling human papillomavirus infection[4]. - The company obtained a total of 18 invention patents in 2023, including 3 international invention patents[5]. - The company launched 18 new invention patents during the reporting period, including 3 international patents[43]. - The company is focusing on the development of recombinant human collagen products, which are expected to enhance its competitive edge in the market[99]. - The company has developed a new type of recombinant type III humanized collagen product, which is the first injectable material of its kind in the market[42]. Financial Performance - The company's operating revenue for 2023 reached ¥780,260,212.25, representing a 99.96% increase compared to ¥390,198,402.96 in 2022[28]. - The net profit attributable to shareholders for 2023 was ¥299,796,292.39, a significant increase of 174.60% from ¥109,175,008.63 in 2022[28]. - The gross profit margin improved to 90.16% in 2023, up from 85.44% in 2022[28]. - The company's net profit surged by 174.26% year-on-year to ¥298,704,880.27, showcasing significant operational efficiency improvements[63]. - The cash flow from operating activities for 2023 was ¥295,566,382.43, a 138.57% increase from ¥123,891,082.75 in 2022[31]. Market and Industry Trends - The medical device industry in China is experiencing rapid growth, with the main business income of medical device manufacturing enterprises reaching approximately CNY 1,240 billion in 2023, a year-on-year increase of about 20%[53]. - The collagen market in China has shown a significant growth trend, with the overall market size increasing from CNY 9.7 billion in 2017 to CNY 39.7 billion in 2022, representing a CAGR of 33%[54]. - By 2027, the market size of recombinant collagen products in China is expected to reach CNY 108.3 billion, accounting for 62.30% of the collagen market[54]. - The global biomaterials market is projected to grow from $35.5 billion in 2020 to $47.5 billion by 2025, with a CAGR of 6.0%[112]. Corporate Developments - The company went public on the Beijing Stock Exchange on July 20, 2023[5]. - The company established a new subsidiary, Jinbo Medical Biomaterials (Beijing) Co., Ltd., to enhance its operational capabilities and future performance[90]. - The company received a high-tech enterprise certificate, allowing it to pay a reduced corporate income tax rate of 15% for the 2023 fiscal year[91]. - The company successfully completed a public offering of 5,000,000 shares on July 20, 2023, followed by an additional 750,000 shares through an over-allotment option on August 18, 2023[23]. Research and Development - The company’s R&D efforts are centered on functional proteins and advanced structural biological materials, enhancing its core competitiveness[46]. - Research and development expenses rose by 87.12% year-on-year to ¥84,976,986.47, reflecting the company's focus on innovative product development and clinical research for new drugs[64]. - The company has increased its R&D personnel from 147 to 173, maintaining a stable proportion of R&D staff at 23.82% of total employees[97]. - The company is conducting clinical research on a broad-spectrum antiviral drug, which is currently in phase III trials, potentially providing a new treatment for coronavirus infections[100]. Shareholder and Profit Distribution - The company approved a stock incentive plan for senior management and core employees, with a maximum allocation of 25,000,000 CNY, representing up to 10% of the public offering[130]. - The profit distribution policy allows for mid-term cash dividends under certain conditions, ensuring that shareholder returns do not affect the company's ongoing operations[157]. - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling an expected cash distribution of 34,043,000 yuan[161]. - The board of directors consists of 9 members, while the supervisory board has 3 members and there are 6 senior management personnel[167]. Social Responsibility and Environmental Measures - The company donated CNY 1 million to the China Charity Federation for earthquake relief efforts in Gansu and Qinghai, demonstrating its commitment to social responsibility[109]. - The company has implemented environmental protection measures, including the purchase of eco-friendly facilities and proper solid waste management, resulting in low carbon emissions during production[110]. Regulatory Environment - The company is subject to multiple regulations, including the Medical Device Production Supervision and Administration Measures, which require registration and compliance for production activities[187]. - The National Development and Reform Commission released the "14th Five-Year Plan for Bioeconomic Development," emphasizing the importance of biomanufacturing and biomedicine in national economic development[190]. - The YY/T 1888-2023 standard for recombinant humanized collagen was announced in January 2023, detailing quality control and technical requirements for medical device materials[192].
锦波生物(832982) - 2023 Q4 - 年度财报